Dyne Therapeutics (NASDAQ:DYN) Director Sells 24,100 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 24,100 shares of Dyne Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $21.10, for a total transaction of $508,510.00. Following the sale, the director directly owned 1,081,044 shares in the company, valued at approximately $22,810,028.40. This trade represents a 2.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $20.61 on Friday. The firm has a 50-day simple moving average of $18.43 and a 200-day simple moving average of $18.09. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -6.40 and a beta of 1.09. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter last year, the business earned ($1.05) EPS. On average, equities analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. TD Cowen began coverage on Dyne Therapeutics in a report on Friday. They issued a “buy” rating for the company. Sanford C. Bernstein lifted their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 15th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Finally, HC Wainwright reduced their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Institutional Trading of Dyne Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Hilton Head Capital Partners LLC acquired a new position in Dyne Therapeutics during the first quarter worth $26,000. Strs Ohio acquired a new position in Dyne Therapeutics during the 4th quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics during the 4th quarter worth about $84,000. Steward Partners Investment Advisory LLC boosted its holdings in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after acquiring an additional 1,440 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.